Literature DB >> 11141496

Biochemical characterization of a neuroserpin variant associated with hereditary dementia.

M Yazaki1, J J Liepnieks, J R Murrell, M Takao, B Guenther, P Piccardo, M R Farlow, B Ghetti, M D Benson.   

Abstract

Neuroserpin isolated from inclusion bodies in the brain of a patient with a neurodegenerative disease was characterized biochemically. The protein consisted of residues 20 to 410 of the neuroserpin precursor deduced from its cDNA sequence indicating the entire molecule was deposited. A minor amount started with residue 19 of the precursor, and the carboxyl terminus was heterogeneous ending at residues 405, 407, 409, and 410. Arg was present at position 52. No normal Ser52 was found indicating that only mutant neuroserpin was present in the inclusion bodies. The three potential Asn glycosylation sites all contained carbohydrate. DNA sequence analysis of exons 2 to 9 of the neuroserpin gene in the proband showed the published normal neuroserpin sequence except for the presence of both adenine and cytosine at the first position of codon 52, that indicates heterozygosity for both the normal Ser(AGT) and variant Arg(CGT) at this position in the expressed protein. Restriction fragment length polymorphism analysis of a polymerase chain reaction product from exon 2 revealed the propositus and his affected sibling both were heterozygous for the mutation whereas 100 unaffected controls were negative. Chemical characterization of the variant neuroserpin will significantly enhance the understanding of this protein in both normal physiology and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11141496      PMCID: PMC1850267          DOI: 10.1016/S0002-9440(10)63961-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells.

Authors:  R M Hill; P K Parmar; L C Coates; E Mezey; J F Pearson; N P Birch
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Basis of the defect in alpha-1-antitrypsin deficiency.

Authors:  O F Bell; R W Carrell
Journal:  Nature       Date:  1973-06-15       Impact factor: 49.962

3.  Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases.

Authors:  S Yokoi; J Austin; F Witmer; M Sakai
Journal:  Arch Neurol       Date:  1968-07

4.  Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea.

Authors:  M Sakai; J Austin; F Witmer; L Trueb
Journal:  Neurology       Date:  1970-02       Impact factor: 9.910

5.  Myoclonus epilepsy with Lafora bodies. An ultrastruc- tural and cytochemical study.

Authors:  G H Collins; R R Cowden; A H Nevis
Journal:  Arch Pathol       Date:  1968-09

6.  Studies of corpora amylacea. I. Isolation and preliminary characterization by chemical and histochemical techniques.

Authors:  M Sakai; J Austin; F Witmer; L Trueb
Journal:  Arch Neurol       Date:  1969-11

7.  A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing.

Authors:  Y Robitaille; S Carpenter; G Karpati; S D DiMauro
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

8.  Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy.

Authors:  M Takao; M D Benson; J R Murrell; M Yazaki; P Piccardo; F W Unverzagt; R L Davis; P D Holohan; D A Lawrence; R Richardson; M R Farlow; B Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  2000-12       Impact factor: 3.685

9.  Neuroserpin, an axonally secreted serine protease inhibitor.

Authors:  T Osterwalder; J Contartese; E T Stoeckli; T B Kuhn; P Sonderegger
Journal:  EMBO J       Date:  1996-06-17       Impact factor: 11.598

10.  Type IV glycogenosis (amylopectinosis). Light and electron microscopic observations.

Authors:  S S Schochet; W F McCormick; H Zellweger
Journal:  Arch Pathol       Date:  1970-10
View more
  10 in total

1.  Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema.

Authors:  Didde Haslund; Laura Barrett Ryø; Sara Seidelin Majidi; Iben Rose; Kristian Alsbjerg Skipper; Tue Fryland; Anja Bille Bohn; Claus Koch; Martin K Thomsen; Yaseelan Palarasah; Thomas J Corydon; Anette Bygum; Lene N Nejsum; Jacob Giehm Mikkelsen
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

2.  Accumulation of mutant neuroserpin precedes development of clinical symptoms in familial encephalopathy with neuroserpin inclusion bodies.

Authors:  Giovanna Galliciotti; Markus Glatzel; Jochen Kinter; Serguei V Kozlov; Paolo Cinelli; Thomas Rülicke; Peter Sonderegger
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

3.  Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin.

Authors:  Shoji Ishigami; Maria Sandkvist; Foon Tsui; Elizabeth Moore; Timothy A Coleman; Daniel A Lawrence
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

4.  The aggregation-prone intracellular serpin SRP-2 fails to transit the ER in Caenorhabditis elegans.

Authors:  Richard M Silverman; Erin E Cummings; Linda P O'Reilly; Mark T Miedel; Gary A Silverman; Cliff J Luke; David H Perlmutter; Stephen C Pak
Journal:  Genetics       Date:  2015-03-18       Impact factor: 4.562

Review 5.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

6.  Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 gene.

Authors:  Matthew C Hagen; Jill R Murrell; Marie-Bernadette Delisle; Eva Andermann; Frederick Andermann; Marie Christine Guiot; Bernardino Ghetti
Journal:  Brain Pathol       Date:  2011-03-24       Impact factor: 6.508

7.  Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.

Authors:  Manuel Yepes; Maria Sandkvist; Timothy A Coleman; Elizabeth Moore; Jiang-Young Wu; David Mitola; Thomas H Bugge; Daniel A Lawrence
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency.

Authors:  Erin E Cummings; Linda P O'Reilly; Dale E King; Richard M Silverman; Mark T Miedel; Cliff J Luke; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

Review 9.  Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges.

Authors:  Lancelot J Millar; Lei Shi; Anna Hoerder-Suabedissen; Zoltán Molnár
Journal:  Front Cell Neurosci       Date:  2017-05-08       Impact factor: 5.505

Review 10.  Neuroserpin: structure, function, physiology and pathology.

Authors:  Emanuela D'Acunto; Annamaria Fra; Cristina Visentin; Mauro Manno; Stefano Ricagno; Giovanna Galliciotti; Elena Miranda
Journal:  Cell Mol Life Sci       Date:  2021-08-17       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.